Skip to main content
SpringerLink
Log in

Prolactinomas in pregnancy: considerations before conception and during pregnancy

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Prolactinomas are the most common pituitary tumors and pathological hyperprolactinemia. Therefore, women harboring prolactinomas frequently present infertility due to the gonadal axis impairment. The gold-standard treatment is dopamine agonist (DA) which can reverse hyperprolactinemia and hypogonadism, and promote tumor shrinkage in the majority of cases. Therefore, reports of pregnancy in such cohort become more common. In this scenario, bromocriptine is still the DA of choice due to its shorter half-life and larger experience as compared to cabergoline. In DA resistant cases, transsphenoidal pituitary surgery is indicated. However, potential risks of DA-induced pregnancies include fetal exposition and symptomatic tumor growth. Dopamine agonist should be discontinued as soon as pregnancy is confirmed in microprolactinomas and intrasellar macroprolactinomas (MAC). Concerning expansive/invasive MAC, DA maintenance should be considered. Periodically clinical evaluation should be performed during pregnancy, being sellar imaging indicated if tumor symptomatic growth is suspected. In such cases, if DA treatment fails, neurosurgery is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352(9138):1455–1461

    CAS  PubMed  Google Scholar 

  2. Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331

    CAS  PubMed  Google Scholar 

  3. Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 122(10):3791–3795

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Millar RP, Sonigo C, Anderson RA, George J, Maione L, Brailly-Tabard S, Chanson P, Binart N, Young J (2017) Hypothalamic-pituitary-ovarian axis reactivation by kisspeptin-10 in hyperprolactinemic women with chronic amenorrhea. J Endocr Soc 1(11):1362–1371

    PubMed  PubMed Central  Google Scholar 

  5. Bronstein M (2010) Disorders of prolactin secretion and prolactinomas. In: Larry Jameson J, De Groot LJ (eds) Endocrinology: adult and pediatric. 1, 6th edn. Philadelphia, Saunders, pp 104–128

    Google Scholar 

  6. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288

    CAS  PubMed  Google Scholar 

  7. Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin N Am 44(1):71–78

    Google Scholar 

  8. Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a PRLoma. Eur J Endocrinol 172(5):R205–R213

    CAS  PubMed  Google Scholar 

  9. Foyouzi N, Frisbaek Y, Norwitz ER (2004) Pituitary gland and pregnancy. Obstet Gynecol Clin N Am 31:873–892 (xi)

    Google Scholar 

  10. Rigg LA, Lein A, Yen SSC (1977) Pattern of increase in circulating PRL levels during human gestation. Am J Obstet Gynecol 129:454–456

    CAS  PubMed  Google Scholar 

  11. Ferriani RA, Silva de Sa MF, Lima Filho EC (1986) A comparative study of longitudinal and cross-sectional changes in plasma levels of PRL and estriol during normal pregnancy. Braz J Med Biol Res 19:183–188

    CAS  PubMed  Google Scholar 

  12. Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HÅ, Idahl A, Lehtinen M, Surcel HM, Fortner RT (2016) Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 16(1):146

    PubMed  PubMed Central  Google Scholar 

  13. Huang W, Molitch ME (2019) Pituitary tumors in pregnancy. Endocrinol Metab Clin N Am 48(3):569–581

    Google Scholar 

  14. Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596

    CAS  PubMed  Google Scholar 

  15. Ikeda H, Watanabe K, Tominaga T et al (2013) Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg 115(9):1621–1625

    PubMed  Google Scholar 

  16. Yan Z, Wang Y, Shou X et al (2015) Effect of transsphenoidal surgery and standard care on fertility related indicators of patients with prolactinomas during childbearing period. Int J Clin Exp Med 8(11):21557–21564

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Yi N, Ji L, Zhang Q, Zhang S, Liu X, Shou X, Lu B (2018) Long-term follow-up of female prolactinoma patients at childbearing age after transsphenoidal surgery. Endocrine 62:76–82

    CAS  PubMed  Google Scholar 

  18. Grand’Maison S, Weber F, Bédard M-J, Mahone M, Godbout A (2015) Pituitary apoplexy in pregnancy: a case series and literature review. Obstet Med 8(4):177–183

    PubMed  PubMed Central  Google Scholar 

  19. Oğuz SH, Soylemezoglu F, Dagdelen S, Erbas T (2019) A case of atypical macroprolactinoma presenting with pituitary apoplexy during pregnancy and review of the literature. Gynecol Endocrinol. https://doi.org/10.1080/09513590.2019.1650339

    Article  PubMed  Google Scholar 

  20. Lamberts SWJ, Klijn JGM, de Lange SA et al (1979) The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. Fertil Steril 31:614–619

    CAS  PubMed  Google Scholar 

  21. O’Donovan PA et al (1986) Apoplexy into a prolactin secreting macroadenoma during early pregnancy with successful outcome: case report. Br J Obstet Gynaecol 93:389–391

    PubMed  Google Scholar 

  22. Freeman R, Wezenter B, Silverstein M et al (1992) Pregnancy-associated subacute hemorrhage into a prolactinoma resulting in diabetes insipidus. Fertil Steril 58:427–429

    CAS  PubMed  Google Scholar 

  23. Gondim J et al (2003) Minimally invasive pituitary surgery in a hemorrhagic necrosis of adenoma during pregnancy. Minim Invasive Neurosurg 46:173–176

    CAS  PubMed  Google Scholar 

  24. Parihar V, Yadav YR, Sharma D (2009) Pituitary apoplexy in a pregnant woman. Ann Indian Acad Neurol 12:54–55

    PubMed  PubMed Central  Google Scholar 

  25. Ginath S, Golan A (2010) Images in clinical medicine. Gestational pituitary tumor apoplexy. N Engl J Med. 363:e10

    PubMed  Google Scholar 

  26. Couture N, Aris-Jilwan N, Serri O (2012) Apoplexy of a microprolactinoma during pregnancy: case report and review of literature. Endocr Pract 18:e147–e150

    PubMed  Google Scholar 

  27. Witek P et al (2012) Transsphenoidal surgery for a life-threatening prolactinomas apoplexy during pregnancy. Neuro Endocrinol Lett 33:483–488

    PubMed  Google Scholar 

  28. Janssen NM, Dreyer K, van der Weiden RM (2012) Management of pituitary tumour apoplexy with bromocriptine in pregnancy. JRSM Short Rep 3:1

    Google Scholar 

  29. Chegour H, El Ansari N (2014) Pituitary apoplexy during pregnancy. Pan Afr Med J 17:211

    PubMed  PubMed Central  Google Scholar 

  30. Tandon A, Alzate J, LaSala P et al (2014) Endoscopic endonasal transsphenoidal resection for pituitary apoplexy during the third trimester of pregnancy. Surg Res Pract 2014:397131

    PubMed  PubMed Central  Google Scholar 

  31. Hayes AR, O’Sullivan AJ, Davies MA (2014) A case of pituitary apoplexy in pregnancy. Endocrinol Diabetes Metab Case Rep 2014:140043

    PubMed  PubMed Central  Google Scholar 

  32. De Ycaza AE, Chang AY, Jensen JR et al (2015) Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women. Case Rep Womens Health 8:9–12

    PubMed  Google Scholar 

  33. Grand’Maison S et al (2015) Pituitary apoplexy in pregnancy: a case series and literature review. Obstet Med 8:177–183

    PubMed  PubMed Central  Google Scholar 

  34. Querol Ripoll R, Camara Gomez R, del Olma Garcıa M et al (2015) Pituitary apoplexy in a pregnant woman with cystic microprolactinoma. Endocrinol Nutr 62:200–202

    PubMed  Google Scholar 

  35. Glezer A, Jallad RS, Machado MC, Fragoso MC, Bronstein MD (2016) Pregnancy and pituitary adenomas. Minerva Endocrinol 41(3):341–350

    PubMed  Google Scholar 

  36. Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with PRLoma—effect of pregnancy and lactation on serum PRL and on tumour growth. Acta Endocrinol (Copenh) 111(4):452–459

    CAS  Google Scholar 

  37. Persiani S, Sassolas G, Piscitelli G et al (1994) Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 83(10):1421–1424

    CAS  PubMed  Google Scholar 

  38. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s012lbl.pdf

  39. https://embryology.med.unsw.edu.au/embryology/index.php/Australian_Drug_Categories

  40. Krupp P, Monka C, Richter K (1988) The safety aspects of infertility treatments. In: Program of the second world congress of gynecology and obstetrics, Rio de Janeiro, p 9

  41. Raymond JP, Goldstein E, Konopka P, Leleu MF, Merce-ron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22:239–246

    CAS  PubMed  Google Scholar 

  42. Canales ES, Garcia IC, Ruiz JE, Zárate A (1981) Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 36:524–526

    CAS  PubMed  Google Scholar 

  43. Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146:935–938

    CAS  PubMed  Google Scholar 

  44. Ruiz-Velasco V, Tolis G (1984) Pregnancy in hyperprolactinemic women. Fertil Steril 41:793–805

    CAS  PubMed  Google Scholar 

  45. Glezer A, Bronstein MD (2014) Prolactinomas, cabergoline, and pregnancy. Endocrine 47:64–69

    CAS  PubMed  Google Scholar 

  46. Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270–273

    CAS  PubMed  Google Scholar 

  47. Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR, Williamson C (2017) Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes. Obstet Gynecol 129(1):185–194

    CAS  PubMed  Google Scholar 

  48. Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8:31–38

    PubMed  Google Scholar 

  49. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) High-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679

    CAS  PubMed  Google Scholar 

  50. Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73:236–242

    CAS  Google Scholar 

  51. Stalldecker G, Gil MSM, Guitelman MA et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13:345–350

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Rua Dr. Enéas de Carvalho Aguiar, no 155, 8° andar, bloco 3 (Endocrinologia), São Paulo, SP, 05403-000, Brazil

    Andrea Glezer & Marcello D. Bronstein

Authors
  1. Andrea Glezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcello D. Bronstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello D. Bronstein.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glezer, A., Bronstein, M.D. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 23, 65–69 (2020). https://doi.org/10.1007/s11102-019-01010-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-019-01010-5

Keywords

Search

Navigation